PiVily Quarterly Report
Implementation and accountability moved to the foreground
The quarter turned completed standards into an implementation agenda and reinforced that postmarketing reporting accountability follows the work across organisational boundaries.
The quarter in one reading
By year-end, the strategic question was no longer whether major standards had changed. It was whether governance, systems, partners and qualified people could translate those changes into controlled practice.
This retrospective edition was reconstructed from official materials and completed on 11 August 2026. It describes the quarter; it does not imply contemporaneous publication.
Material signals
What moved—and why it mattered.
The ICH agenda shifted from adoption toward regional use.
The November 2025 ICH Assembly confirmed final guidelines adopted during the year, including E2D(R1) and M14, and continued work on related implementation and training materials.
ICH: ICH Assembly meeting, Singapore — November 2025 ICH: E2D(R1) reaches Step 4 ICH: M14 reaches Step 4
Step 4 creates a common standard; it does not synchronise every regional effective date or internal change programme. Implementation intelligence becomes a governance discipline of its own.
Who owns the cross-regional implementation map, and how are dependencies and differing dates controlled?
Inspection scope remained wider than the sponsor boundary.
FDA's postmarketing adverse-event reporting compliance programme states that inspections may include entities contracted to process adverse-event information and emphasises complete, accurate and timely reporting.
FDA: Postmarketing adverse-event reporting compliance programme
Outsourcing changes who performs the task, not the need to understand data flows, deviations, reconciliations, escalation and decision records across the end-to-end system.
Can a qualified reviewer reconstruct a safety record across sponsor, vendor and supply-chain interfaces without assembling it manually after the fact?
The year closed with greater specificity around evidence and risk control.
EMA's 2025 GVP work included new considerations and addenda addressing personal-data masking and embryo-fetal risk minimisation, alongside continued implementation discussion with stakeholders.
The direction is toward controls that can be explained and evaluated—not merely documented as present.
Does the governance model test whether a risk control works in practice, or only whether the document exists?
Next-quarter watch
Questions to carry forward.
- Evidence that revised standards are embedded rather than administratively closed
- Inspection attention at sponsor-vendor and global-local interfaces
- Governance models capable of evaluating control effectiveness
Method & source register
Trace the reading back to the record.
PiVily selects developments for system-level relevance to human pharmacovigilance. Facts are attributed to official publishers; interpretation is editorial. This is not an exhaustive jurisdictional change log or organisation-specific advice.